Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Thoracic 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 3Neoplasms 2Stomach Neoplasms 1Sarcoma 1Mesothelioma 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Adenoma, Islet Cell 1

Interventions

Fluorodeoxyglucose F18 2tivozanib 1tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1regorafenib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lactones 1Irinotecan 1Interleukin-2 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × PM 01183 × NET × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡